ArticleJournal of gastrointestinal oncology2026
Assessment of colorectal cancer recurrence risk following solid organ transplantation.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prior studies have reported solid organ transplant (SOT) recipients have increased rates of colorectal cancer (CRC). While this increased incidence is established, the recurrence risk following curative-intent treatment for post-SOT CRC remains poorly defined. Therefore, the aim of this study was to evaluate CRC recurrence in addition to exploring clinical and molecular factors associated with CRC recurrence in patients with prior SOT. Methods: Multi-institutional retrospective cohort study of adult patients diagnosed with CRC following prior SOT between 2016-2025 at The Johns Hopkins Hospital and the University of Wisconsin Hospitals and Clinics. Demographic, clinical, molecular genomics, and immunosuppression data were obtained from electronic medical records. Recurrence risk was compared to population study benchmark recurrence rates using standardized incidence ratios (SIRs). Results: This study included 53 SOT recipients with subsequent CRC diagnosis. Recurrence rates exceeded population benchmarks across all disease stages, particularly in stage I and II disease demonstrating SIRs of 3.66 and 2.55 respectively. KRAS and APC mutations were associated with increased recurrence risk [hazard ratio (HR) =13.58, P=0.002; HR =5.03, P=0.02, respectively], while no patients with BRAF mutations recurred (n=8, P<0.001). All BRAF mutations occurred in tumors that were mismatch repair deficient (MMRd). Mismatch repair (MMR) status and immunosuppression characteristics did not predict disease recurrence in the study cohort. Conclusions: SOT recipients showed a trend towards heightened CRC recurrence risk compared to population benchmarks. KRAS, APC, and BRAF mutational status all influenced recurrence risk in this cohort. Despite a lack of association between immunosuppression variables and recurrence, we suspect diminished immune surveillance is implicated in this elevated relapse risk. Strategies to address this, including immunosuppression reduction in the post-SOT CRC population, may be effective in reducing this elevated relapse risk but require validation in prospective multi-institutional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.